Log in

NYSE:OMIOwens & Minor Competitors & Alternatives

$7.40
-0.31 (-4.02 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.39
Now: $7.40
$7.73
50-Day Range
$7.03
MA: $7.53
$8.51
52-Week Range
$2.43
Now: $7.40
$9.69
Volume688,400 shs
Average Volume1.18 million shs
Market Capitalization$466.27 million
P/E RatioN/A
Dividend Yield0.14%
Beta0.14

Competitors

Owens & Minor (NYSE:OMI) Vs. SEM, CMD, XNCR, LGND, ATRC, and THC

Should you be buying OMI stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Owens & Minor, including Select Medical (SEM), Cantel Medical (CMD), Xencor (XNCR), Ligand Pharmaceuticals (LGND), AtriCure (ATRC), and Tenet Healthcare (THC).

Select Medical (NYSE:SEM) and Owens & Minor (NYSE:OMI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Earnings and Valuation

This table compares Select Medical and Owens & Minor's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Select Medical$5.45 billion0.34$148.45 million$1.2411.27
Owens & Minor$9.21 billion0.05$-62,370,000.00$0.5613.21

Select Medical has higher earnings, but lower revenue than Owens & Minor. Select Medical is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Select Medical and Owens & Minor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Select Medical11402.50
Owens & Minor03102.25

Select Medical presently has a consensus price target of $22.00, suggesting a potential upside of 57.48%. Owens & Minor has a consensus price target of $8.25, suggesting a potential upside of 11.49%. Given Select Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Select Medical is more favorable than Owens & Minor.

Volatility and Risk

Select Medical has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Profitability

This table compares Select Medical and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Select Medical2.90%18.74%2.48%
Owens & Minor-0.65%7.44%0.93%

Insider and Institutional Ownership

76.1% of Select Medical shares are owned by institutional investors. Comparatively, 87.5% of Owens & Minor shares are owned by institutional investors. 19.7% of Select Medical shares are owned by insiders. Comparatively, 2.2% of Owens & Minor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Select Medical beats Owens & Minor on 12 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and Owens & Minor (NYSE:OMI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility & Risk

Cantel Medical has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cantel Medical and Owens & Minor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cantel Medical$918.16 million1.99$55.04 million$2.3718.27
Owens & Minor$9.21 billion0.05$-62,370,000.00$0.5613.21

Cantel Medical has higher earnings, but lower revenue than Owens & Minor. Owens & Minor is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.4% of Cantel Medical shares are held by institutional investors. Comparatively, 87.5% of Owens & Minor shares are held by institutional investors. 10.9% of Cantel Medical shares are held by company insiders. Comparatively, 2.2% of Owens & Minor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cantel Medical and Owens & Minor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cantel Medical00203.00
Owens & Minor03102.25

Cantel Medical presently has a consensus price target of $65.00, suggesting a potential upside of 50.12%. Owens & Minor has a consensus price target of $8.25, suggesting a potential upside of 11.49%. Given Cantel Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cantel Medical is more favorable than Owens & Minor.

Dividends

Cantel Medical pays an annual dividend of $0.21 per share and has a dividend yield of 0.5%. Owens & Minor pays an annual dividend of $0.01 per share and has a dividend yield of 0.1%. Cantel Medical pays out 8.9% of its earnings in the form of a dividend. Owens & Minor pays out 1.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cantel Medical has raised its dividend for 6 consecutive years and Owens & Minor has raised its dividend for 20 consecutive years.

Profitability

This table compares Cantel Medical and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cantel Medical2.75%12.32%5.10%
Owens & Minor-0.65%7.44%0.93%

Summary

Cantel Medical beats Owens & Minor on 14 of the 17 factors compared between the two stocks.

Xencor (NASDAQ:XNCR) and Owens & Minor (NYSE:OMI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

90.0% of Xencor shares are owned by institutional investors. Comparatively, 87.5% of Owens & Minor shares are owned by institutional investors. 3.7% of Xencor shares are owned by insiders. Comparatively, 2.2% of Owens & Minor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Xencor and Owens & Minor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Xencor31702.36
Owens & Minor03102.25

Xencor currently has a consensus target price of $40.50, indicating a potential upside of 26.76%. Owens & Minor has a consensus target price of $8.25, indicating a potential upside of 11.49%. Given Xencor's stronger consensus rating and higher possible upside, equities analysts clearly believe Xencor is more favorable than Owens & Minor.

Risk & Volatility

Xencor has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Valuation and Earnings

This table compares Xencor and Owens & Minor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$156.70 million11.62$26.88 million$0.4669.46
Owens & Minor$9.21 billion0.05$-62,370,000.00$0.5613.21

Xencor has higher earnings, but lower revenue than Owens & Minor. Owens & Minor is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Xencor and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Xencor-79.39%-10.40%-9.24%
Owens & Minor-0.65%7.44%0.93%

Summary

Xencor beats Owens & Minor on 8 of the 14 factors compared between the two stocks.

Ligand Pharmaceuticals (NASDAQ:LGND) and Owens & Minor (NYSE:OMI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Valuation and Earnings

This table compares Ligand Pharmaceuticals and Owens & Minor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$120.28 million14.97$629.30 million$2.1153.18
Owens & Minor$9.21 billion0.05$-62,370,000.00$0.5613.21

Ligand Pharmaceuticals has higher earnings, but lower revenue than Owens & Minor. Owens & Minor is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.5% of Owens & Minor shares are owned by institutional investors. 8.4% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of Owens & Minor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ligand Pharmaceuticals and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ligand Pharmaceuticals-55.63%3.68%2.03%
Owens & Minor-0.65%7.44%0.93%

Risk & Volatility

Ligand Pharmaceuticals has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Ligand Pharmaceuticals and Owens & Minor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ligand Pharmaceuticals02402.67
Owens & Minor03102.25

Ligand Pharmaceuticals currently has a consensus target price of $169.00, indicating a potential upside of 50.61%. Owens & Minor has a consensus target price of $8.25, indicating a potential upside of 11.49%. Given Ligand Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Ligand Pharmaceuticals is more favorable than Owens & Minor.

Summary

Ligand Pharmaceuticals beats Owens & Minor on 9 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and Owens & Minor (NYSE:OMI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Earnings and Valuation

This table compares AtriCure and Owens & Minor's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$230.81 million7.59$-35,190,000.00($1.07)-40.88
Owens & Minor$9.21 billion0.05$-62,370,000.00$0.5613.21

AtriCure has higher earnings, but lower revenue than Owens & Minor. AtriCure is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.9% of AtriCure shares are held by institutional investors. Comparatively, 87.5% of Owens & Minor shares are held by institutional investors. 5.8% of AtriCure shares are held by company insiders. Comparatively, 2.2% of Owens & Minor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares AtriCure and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtriCure-19.98%-19.19%-9.40%
Owens & Minor-0.65%7.44%0.93%

Volatility and Risk

AtriCure has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for AtriCure and Owens & Minor, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtriCure01802.89
Owens & Minor03102.25

AtriCure currently has a consensus price target of $46.2222, indicating a potential upside of 5.67%. Owens & Minor has a consensus price target of $8.25, indicating a potential upside of 11.49%. Given Owens & Minor's higher possible upside, analysts plainly believe Owens & Minor is more favorable than AtriCure.

Tenet Healthcare (NYSE:THC) and Owens & Minor (NYSE:OMI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Tenet Healthcare and Owens & Minor, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tenet Healthcare06502.45
Owens & Minor03102.25

Tenet Healthcare currently has a consensus price target of $28.1818, indicating a potential upside of 58.50%. Owens & Minor has a consensus price target of $8.25, indicating a potential upside of 11.49%. Given Tenet Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Tenet Healthcare is more favorable than Owens & Minor.

Earnings and Valuation

This table compares Tenet Healthcare and Owens & Minor's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenet Healthcare$18.48 billion0.10$-232,000,000.00$2.686.63
Owens & Minor$9.21 billion0.05$-62,370,000.00$0.5613.21

Owens & Minor has lower revenue, but higher earnings than Tenet Healthcare. Tenet Healthcare is trading at a lower price-to-earnings ratio than Owens & Minor, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Tenet Healthcare has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Owens & Minor has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500.

Insider & Institutional Ownership

99.6% of Tenet Healthcare shares are held by institutional investors. Comparatively, 87.5% of Owens & Minor shares are held by institutional investors. 1.7% of Tenet Healthcare shares are held by company insiders. Comparatively, 2.2% of Owens & Minor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Tenet Healthcare and Owens & Minor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tenet Healthcare-0.65%65.69%1.54%
Owens & Minor-0.65%7.44%0.93%

Summary

Tenet Healthcare beats Owens & Minor on 10 of the 13 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Select Medical logo
SEM
Select Medical
2.2$13.97-1.3%$1.85 billion$5.45 billion11.64Increase in Short Interest
Cantel Medical logo
CMD
Cantel Medical
2.3$43.30-1.2%$1.83 billion$918.16 million64.63Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.6$31.95-3.1%$1.82 billion$156.70 million-29.86Analyst Report
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$112.21-0.2%$1.80 billion$120.28 million-32.62Analyst Downgrade
Unusual Options Activity
AtriCure logo
ATRC
AtriCure
1.4$43.74-0.9%$1.77 billion$230.81 million-36.45Analyst Downgrade
Tenet Healthcare logo
THC
Tenet Healthcare
1.9$17.78-5.5%$1.76 billion$18.48 billion-15.07Decrease in Short Interest
Analyst Revision
Heavy News Reporting
USANA Health Sciences logo
USNA
USANA Health Sciences
1.2$82.29-0.2%$1.73 billion$1.06 billion17.73Analyst Downgrade
Magellan Health logo
MGLN
Magellan Health
1.7$68.95-4.0%$1.72 billion$7.16 billion23.06
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$14.88-2.5%$1.72 billion$320,000.00-11.36Analyst Downgrade
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.2$21.13-2.4%$1.70 billion$250,000.00-19.56Analyst Report
SWTX
SpringWorks Therapeutics
1.5$39.42-5.3%$1.70 billionN/A-11.10
Myovant Sciences logo
MYOV
Myovant Sciences
1.9$18.70-3.4%$1.68 billionN/A-5.55Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$103.91-3.6%$1.66 billionN/A-15.26Analyst Downgrade
Glaukos logo
GKOS
Glaukos
1.1$37.96-1.4%$1.66 billion$236.98 million-40.38
IMAB
I-Mab
1.2$29.50-2.7%$1.64 billion$4.31 million-1.02Lockup Expiration
Heavy News Reporting
RVMD
Bill.com
1.7$27.66-2.4%$1.63 billionN/A0.00
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.7$11.98-4.3%$1.63 billion$335 million-5.42Analyst Upgrade
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.4$8.06-3.8%$1.63 billion$31.43 million-4.63Analyst Upgrade
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.5$24.43-2.5%$1.62 billion$60,000.00-8.79Analyst Downgrade
Unusual Options Activity
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.7$39.92-1.2%$1.61 billionN/A-16.03Analyst Downgrade
Heavy News Reporting
Zymeworks logo
ZYME
Zymeworks
1.7$33.19-5.7%$1.60 billion$29.54 million-8.53Analyst Report
Unusual Options Activity
Heavy News Reporting
BEAM
Beam Therapeutics
0.6$26.73-14.4%$1.57 billion$20,000.00-1.90
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.4$9.86-1.3%$1.57 billion$428.41 million18.60Analyst Downgrade
SY
So-Young International
0.8$15.32-5.2%$1.56 billion$165.42 million139.29
CareDx logo
CDNA
CareDx
1.3$33.93-3.6%$1.56 billion$127.07 million-70.69Insider Selling
Cytokinetics logo
CYTK
Cytokinetics
1.6$25.50-2.4%$1.55 billion$26.87 million-11.38Analyst Upgrade
Insider Selling
High Trading Volume
Decrease in Short Interest
Heavy News Reporting
Zogenix logo
ZGNX
Zogenix
2.0$27.24-2.1%$1.54 billion$3.65 million-2.89Analyst Downgrade
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.2$10.69-1.9%$1.53 billion$102.43 million-12.88Analyst Report
Analyst Revision
Heavy News Reporting
Epizyme logo
EPZM
Epizyme
1.6$15.16-0.1%$1.53 billion$23.80 million-7.47Analyst Downgrade
Luminex logo
LMNX
Luminex
1.2$33.36-3.1%$1.53 billion$334.64 million-222.39Insider Selling
Analyst Revision
Mesoblast logo
MESO
Mesoblast
1.2$13.02-0.6%$1.53 billion$16.72 million-20.34
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.4$21.57-4.7%$1.51 billion$42.12 million-15.41Analyst Downgrade
MacroGenics logo
MGNX
MacroGenics
1.3$30.52-0.5%$1.51 billion$64.19 million-9.88Increase in Short Interest
Heavy News Reporting
Veracyte logo
VCYT
Veracyte
1.0$29.54-0.2%$1.48 billion$120.37 million-64.22Analyst Upgrade
Insider Selling
ZNTL
Passage Bio
1.1$41.13-3.4%$1.48 billionN/A0.00Heavy News Reporting
ZEALAND PHARMA/S logo
ZEAL
ZEALAND PHARMA/S
0.8$36.60-1.0%$1.45 billion$6.20 million-13.56
MEDNAX logo
MD
MEDNAX
1.7$16.98-3.2%$1.45 billion$3.51 billion-1.10Increase in Short Interest
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.3$25.34-2.9%$1.45 billion$410,000.00-6.40Analyst Upgrade
Heavy News Reporting
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$43.86-0.4%$1.44 billion$252 million-4.09
SILK
Silk Road Medical
1.3$44.99-1.6%$1.44 billion$63.35 million-35.43Analyst Downgrade
Decrease in Short Interest
Analyst Revision
Heavy News Reporting
Regenxbio logo
RGNX
Regenxbio
1.5$38.36-1.4%$1.43 billion$35.23 million-13.80
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$51.70-2.0%$1.43 billion$148.36 million-5.37Increase in Short Interest
AXNX
Axonics Modulation Technologies
1.4$39.34-4.9%$1.42 billion$13.82 million-14.31Analyst Upgrade
Heavy News Reporting
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.6$15.76-0.7%$1.42 billion$145.97 million-6.94
BioTelemetry logo
BEAT
BioTelemetry
1.8$41.52-0.4%$1.42 billion$439.11 million60.17Analyst Upgrade
Unusual Options Activity
Portola Pharmaceuticals logo
PTLA
Portola Pharmaceuticals
1.5$18.03-0.0%$1.42 billion$116.64 million-4.78
SWAV
Shockwave Medical
1.3$43.96-6.9%$1.40 billion$42.93 million-22.90Analyst Report
High Trading Volume
Decrease in Short Interest
Heavy News Reporting
Addus Homecare logo
ADUS
Addus Homecare
1.3$89.64-0.4%$1.39 billion$518.12 million46.45Analyst Upgrade
Nantkwest logo
NK
Nantkwest
2.0$13.80-2.1%$1.39 billion$40,000.00-20.29Analyst Report
Insider Selling
Increase in Short Interest
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.8$19.17-1.7%$1.38 billion$40.89 million-6.57
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.